Regenxbio Inc (NASDAQ:RGNX) SVP Curran Simpson sold 43,832 shares of Regenxbio stock in a transaction dated Tuesday, February 5th. The stock was sold at an average price of $50.08, for a total transaction of $2,195,106.56. Following the sale, the senior vice president now directly owns 47,950 shares of the company’s stock, valued at approximately $2,401,336. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Curran Simpson also recently made the following trade(s):

  • On Friday, November 16th, Curran Simpson sold 32,882 shares of Regenxbio stock. The stock was sold at an average price of $63.76, for a total transaction of $2,096,556.32.

NASDAQ RGNX opened at $44.87 on Friday. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -18.31 and a beta of 0.41. Regenxbio Inc has a 12-month low of $24.30 and a 12-month high of $85.10.

Regenxbio (NASDAQ:RGNX) last posted its quarterly earnings data on Wednesday, November 7th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.86) by $0.30. The firm had revenue of $5.31 million during the quarter. Regenxbio had a net margin of 44.30% and a return on equity of 22.52%. On average, equities research analysts expect that Regenxbio Inc will post 2.34 earnings per share for the current fiscal year.

Several analysts recently commented on the stock. Zacks Investment Research raised shares of Regenxbio from a “hold” rating to a “buy” rating and set a $78.00 target price for the company in a report on Wednesday, November 7th. ValuEngine raised shares of Regenxbio from a “hold” rating to a “buy” rating in a report on Monday, February 4th. BidaskClub downgraded shares of Regenxbio from a “sell” rating to a “strong sell” rating in a report on Wednesday, January 30th. Finally, Raymond James set a $96.00 target price on shares of Regenxbio and gave the stock a “buy” rating in a report on Thursday, November 8th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Regenxbio currently has a consensus rating of “Hold” and a consensus target price of $74.81.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. boosted its holdings in Regenxbio by 2.0% in the 4th quarter. BlackRock Inc. now owns 4,822,962 shares of the biotechnology company’s stock valued at $202,322,000 after purchasing an additional 95,917 shares during the period. 361 Capital LLC boosted its holdings in Regenxbio by 70.3% in the 4th quarter. 361 Capital LLC now owns 42,604 shares of the biotechnology company’s stock valued at $1,787,000 after purchasing an additional 17,582 shares during the period. First Trust Advisors LP bought a new stake in Regenxbio in the 4th quarter valued at about $2,680,000. Prudential Financial Inc. boosted its holdings in Regenxbio by 0.5% in the 4th quarter. Prudential Financial Inc. now owns 150,770 shares of the biotechnology company’s stock valued at $6,324,000 after purchasing an additional 700 shares during the period. Finally, Piedmont Investment Advisors Inc. boosted its holdings in Regenxbio by 5.8% in the 4th quarter. Piedmont Investment Advisors Inc. now owns 7,198 shares of the biotechnology company’s stock valued at $302,000 after purchasing an additional 395 shares during the period. 79.14% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2019/02/09/curran-simpson-sells-43832-shares-of-regenxbio-inc-rgnx-stock.html.

About Regenxbio

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.

Read More: Capital Gains

Insider Buying and Selling by Quarter for Regenxbio (NASDAQ:RGNX)

Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.